07:13 EST Neumora: KOASTAL-1 study did not demonstrate SS improvement on primary endpoint
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics Inc put volume heavy and directionally bearish
- J&J trial news may have positive read for Neumora Therapeutics, says RBC Capital
- Neumora Therapeutics Reports Q3 2024 Financial Results
- Neumora Therapeutics reports Q3 EPS (45c), consensus (39c)
- Neumora Therapeutics downgraded to Neutral from Overweight at JPMorgan